COVID-19 is an emerging, rapidly evolving situation.

What people with cancer should know: https://www.cancer.gov/coronavirus

Guidance for cancer researchers: https://www.cancer.gov/coronavirus-researchers

Get the latest public health information from CDC: https://www.coronavirus.gov

Get the latest research information from NIH: https://www.nih.gov/coronavirus

David Stevens

David Stevens, Ph.D.David Stevens, PhD
Scientist I, Pharmacology & Toxicology

Dr. Stevens develops novel drug formulation strategies including micelle formulations and polymeric prodrugs for the improved delivery of small molecule chemotherapeutics. His areas of expertise include polymer and organic chemistry, polymeric nanoparticle formulations, analytical chemistry, and pharmaceutical sciences.

Prior to joining the NCL, Dr. Stevens conducted research developing targeted and sustained-release nanoformulations for various medical applications including cancer, diabetes, and bone healing. He received his B.S. in chemistry from the University of St. Thomas and his Ph.D. in pharmacology from Vanderbilt University, specializing in crosslinked polymeric nanoparticle systems.